Kim Yun Hak, Goh Tae Sik, Lee Chi-Seung, Oh Sae Ock, Kim Jeung Il, Jeung Seung Hyeon, Pak Kyoungjune
BEER, Busan Society of Evidence-Based Medicine and Research, Busan, Republic of Korea.
Department of Anatomy, School of Medicine, Pusan National University, Yangsan, Gyeongnam, Republic of Korea.
Oncotarget. 2017 Jan 31;8(5):8726-8737. doi: 10.18632/oncotarget.14429.
Osteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.
Sources from MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) were searched. Studies of osteosarcoma with results of miRNA and studies that reported survival data were included and two authors performed the data extraction independently. Any discrepancies were resolved by a consensus. The outcome was overall survival and event-free survival assessed using hazard ratios (HRs).
After reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible in this study. The pooled HR for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p<0.00001, I2=79%) for patients of osteosarcoma with lower expression of miRNA. However, the pooled HR for events was not significant (HR 0.97, 0.63-1.48, p=0.87, χ2=72.65, p<0.00001, I2=79%). In pathway analysis of miRNAs, miRNA449a, 199-5p, 542-5p have common target genes.
Expression level of miRNA in patients of osteosarcoma is important as a prognostic factor.
骨肉瘤是最常见的原发性骨恶性肿瘤。我们对骨肉瘤患者中miRNA改变的预后价值进行了荟萃分析。
检索MEDLINE（从创刊至2016年8月）和EMBASE（从创刊至2016年8月）数据库。纳入有关骨肉瘤且有miRNA结果的研究以及报告生存数据的研究，由两位作者独立进行数据提取。任何差异通过协商解决。结局指标为使用风险比（HRs）评估的总生存期和无事件生存期。
在查阅65篇文章的全文后，本研究纳入了25项研究，共2278例患者。对于miRNA表达较低的骨肉瘤患者，采用随机效应模型（χ2=113.08，p<0.00001，I2=79%），死亡的合并HR为1.40（95%置信区间[CI]1.01 - 1.94，p = 0.04）。然而，事件的合并HR无统计学意义（HR 0.97，0.63 - 1.48，p = 0.87，χ2=72.65，p<0.00001，I2=79%）。在miRNA的通路分析中，miRNA449a、199 - 5p、542 - 5p具有共同的靶基因。
骨肉瘤患者中miRNA的表达水平作为预后因素具有重要意义。
